Pfizer (PFE) Expected to Announce Quarterly Earnings on Tuesday

Pfizer (NYSE:PFE) will likely be announcing its Q4 2025 results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of $0.56 per share and revenue of $16.9329 billion for the quarter. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 3, 2026 at 10:00 AM ET.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Trading Up 0.9%

Shares of PFE stock opened at $25.87 on Tuesday. The firm has a market capitalization of $147.09 billion, a P/E ratio of 15.04 and a beta of 0.47. Pfizer has a 1 year low of $20.92 and a 1 year high of $27.69. The firm’s fifty day simple moving average is $25.41 and its 200 day simple moving average is $25.00. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s payout ratio is presently 100.00%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Faithward Advisors LLC bought a new stake in Pfizer during the 3rd quarter worth about $216,000. Eaton Financial Holdings Company LLC raised its position in Pfizer by 18.1% in the 3rd quarter. Eaton Financial Holdings Company LLC now owns 27,962 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 4,291 shares during the last quarter. Financial Engines Advisors L.L.C. lifted its holdings in Pfizer by 29.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 20,154 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 4,585 shares in the last quarter. Abel Hall LLC raised its position in shares of Pfizer by 1.7% during the third quarter. Abel Hall LLC now owns 26,342 shares of the biopharmaceutical company’s stock worth $671,000 after acquiring an additional 442 shares during the last quarter. Finally, Morningstar Investment Management LLC boosted its holdings in Pfizer by 472.1% in the third quarter. Morningstar Investment Management LLC now owns 326,558 shares of the biopharmaceutical company’s stock valued at $8,321,000 after acquiring an additional 269,476 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Morgan Stanley cut their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $27.88.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.